MAIA — Maia Biotechnology Share News
0.000.00%
Last trade - 00:00Brief: MAIA Biotechnology Announces Positive Survival Updates In Phase 2 Study Of Thio In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology's Telomere Targeting Functionality Is Shown Viable By FDA’S Approval Of A Telomerase Inhibitor Agent Therapy
Brief: MAIA Biotechnology Reveals New Clinical Data Showing THIO’s Strong Efficacy in Non-Small Cell Lung Cancer
Brief: MAIA Biotechnology Announces $1.3 Mln Private Placement
Brief: Maia Biotechnology May Offer Shares Of Common Stock Having Offering Price Of Up To $5.0 Million From Time To Time-SEC Filing
Brief: Maia Biotechnology Increased Maximum Aggregate Offering Price Of Shares Of Common Stock, Issuable Under At Market Offering Agreement
Brief: MAIA Biotechnology Announces Strong Efficacy Of THIO As Third-Line Treatment For Non-Small Cell Lung Cancer Patients
Brief: MAIA Biotechnology Says Co's THIO-101 Phase 2 Clinical Trial Nears Completion
MAIA Biotechnology gains on positive interim data for cancer drug
Brief: Maia Biotechnology Enters 2024 With Robust Clinical Pipeline In Multiple Hard-To-Treat Cancer Indications
Brief: MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
Brief: Joseph Mcguire And Mihail Obrocea Terminated From Their Positions at Maia Biotechnology
Brief: FDA Grants Orphan Drug Designation To Maia Biotechnology For THIO As A Treatment For Glioblastoma
Maia climbs after positive data from lung cancer treatment trial
Brief: Maia Biotech Announces Positive Preliminary Efficacy Data For Ongoing Thio-101 Phase 2 Trial
Brief: Maia Biotechnology Reveals New Data Showing Thio’S Potent Anticancer Activity In Aggressive Pediatric Brain Cancer
Brief: Maia Biotechnology Accelerates Enrollment In Thio-101 Phase Ii Clinical Trial As Efficacy Is Observed In Dosed Patients
Brief: Maia Biotechnology Announces Potent Anticancer Activity Of THIO In Gliomas
Brief: Maia Biotechnology Announces FDA Clearance Of Ind Application For Thio, A Telomere Targeting Agent For The Treatment Of Non-Small Cell Lung Cancer